{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bintrafusp+alfa%2FM7824&page=2", "query": { "intervention": "Bintrafusp alfa/M7824", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 34, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bintrafusp+alfa%2FM7824&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bintrafusp+alfa%2FM7824&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T23:47:54.892Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04574583", "title": "Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta \"Trap\"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Cancer", "Solid Tumors" ], "interventions": [ { "name": "SX-682", "type": "DRUG" }, { "name": "M7824", "type": "DRUG" }, { "name": "MVA-BN-CV301", "type": "BIOLOGICAL" }, { "name": "recombinant fowlpox viral (FPV)-CV301", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2020-11-24", "completion_date": "2023-05-19", "has_results": true, "last_update_posted_date": "2025-02-03", "last_synced_at": "2026-10-03T23:47:54.892Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04574583" }, { "nct_id": "NCT04066491", "title": "Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Biliary Tract Cancer", "Cholangiocarcinoma", "Gallbladder Cancer" ], "interventions": [ { "name": "M7824", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 309, "start_date": "2019-09-20", "completion_date": "2022-11-10", "has_results": true, "last_update_posted_date": "2023-11-14", "last_synced_at": "2026-10-03T23:47:54.892Z", "location_count": 12, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 9 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04066491" }, { "nct_id": "NCT04220775", "title": "Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Head and Neck Squamous Cell Carcinoma", "Second Primary Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Bintrafusp Alfa", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2020-03-18", "completion_date": "2022-10-03", "has_results": true, "last_update_posted_date": "2024-11-07", "last_synced_at": "2026-10-03T23:47:54.892Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04220775" }, { "nct_id": "NCT04327986", "title": "Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Histologically or Cytologically Confirmed Pancreatic Cancer", "Unresectable or Borderline Resectable Pancreatic Cancer", "Pancreatic Neoplasms", "Pancreatic Cancer", "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "M7824", "type": "DRUG" }, { "name": "M9241", "type": "DRUG" }, { "name": "SBRT", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2021-06-15", "completion_date": "2022-02-03", "has_results": true, "last_update_posted_date": "2022-05-18", "last_synced_at": "2026-10-03T23:47:54.892Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04327986" }, { "nct_id": "NCT04708067", "title": "Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Intrahepatic Cholangiocarcinoma", "Metastatic Intrahepatic Cholangiocarcinoma", "Stage III Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8" ], "interventions": [ { "name": "Bintrafusp Alfa", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2021-08-31", "completion_date": "2027-02-02", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-03T23:47:54.892Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04708067" }, { "nct_id": "NCT03579472", "title": "M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Triple-Negative Breast Carcinoma", "Prognostic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Bintrafusp Alfa", "type": "DRUG" }, { "name": "Eribulin Mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2018-05-30", "completion_date": "2022-09-21", "has_results": false, "last_update_posted_date": "2022-10-31", "last_synced_at": "2026-10-03T23:47:54.892Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03579472" }, { "nct_id": "NCT03840902", "title": "M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "M7824", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Intensity Modulated Radiation Therapy (IMRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2019-04-16", "completion_date": "2023-02-17", "has_results": true, "last_update_posted_date": "2024-01-16", "last_synced_at": "2026-10-03T23:47:54.892Z", "location_count": 21, "location_summary": "Orange, California • Santa Monica, California • Colorado Springs, Colorado + 17 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03840902" }, { "nct_id": "NCT04296942", "title": "BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Triple Negative Breast Cancer", "HER2+ Breast Cancer", "Hormone Receptor Negative Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Brachyury-TRICOM", "type": "BIOLOGICAL" }, { "name": "Entinostat", "type": "DRUG" }, { "name": "M7824", "type": "BIOLOGICAL" }, { "name": "Ado-trastuzumab emtansine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-05-04", "completion_date": "2021-10-22", "has_results": true, "last_update_posted_date": "2022-01-11", "last_synced_at": "2026-10-03T23:47:54.892Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04296942" }, { "nct_id": "NCT04246489", "title": "Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uterine Cervical Neoplasms" ], "interventions": [ { "name": "Bintrafusp alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 146, "start_date": "2020-03-30", "completion_date": "2022-12-14", "has_results": true, "last_update_posted_date": "2023-10-23", "last_synced_at": "2026-10-03T23:47:54.892Z", "location_count": 11, "location_summary": "Fayetteville, Arkansas • Little Rock, Arkansas • Stanford, California + 8 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Stanford", "state": "California" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Farmington Hills", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04246489" }, { "nct_id": "NCT03493945", "title": "Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer", "Prostate Cancer", "Prostate Neoplasm", "Advanced Solid Tumor", "Solid Tumor", "Non-metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "M7824", "type": "BIOLOGICAL" }, { "name": "N-803", "type": "DRUG" }, { "name": "MVA-BN-Brachyury", "type": "BIOLOGICAL" }, { "name": "FPV-Brachyury", "type": "BIOLOGICAL" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Ibuprofen", "type": "DRUG" }, { "name": "Naproxen", "type": "DRUG" }, { "name": "Benadryl", "type": "OTHER" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone scan", "type": "DIAGNOSTIC_TEST" }, { "name": "CT chest, abdomen and pelvis", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 59, "start_date": "2018-05-01", "completion_date": "2024-10-08", "has_results": true, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-10-03T23:47:54.892Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03493945" } ] }